Although partial thyroidectomy has lower operative risk, it potentially caries the risk of leaving residual malignancy. 
Introduction
Thyroid cancer accounts for 90% of all endocrine system cancers and 0.2% of deaths related to cancer with a worldwide prevalence of 1% [1] . General approach for the management of differentiated thyroid cancer (DTC) in high-risk patients is radioactive iodine (RAI) therapy after total or subtotal thyroidectomy and thyroid stimulating hormone (TSH) suppression with thyroid hormone replacement [2] .
The main target in DTC therapy is complete removal of primary tumor by keeping complication risk at a minimum level and to provide better quality of life. The residual thyroid tissue carries recurrence risk for the cases in whom total thyroidectomy cannot be performed [3] . Therefore, in patients with residual tissue, completion thyroidectomy or RAI ablation therapy should be performed. But it is still controversial that these patients should have a completion thyroidectomy or should have a more conservative approach, such as RAI ablation. Awareness of whether or not cancerous tissue presents in residual thyroid tissue can help us in determining the treatment approach.
Thyroglobulin (Tg) is a glycoprotein secreted by normal or neoplastic follicular cells of thyroid gland. Measurable level of Tg after total thyroidectomy indicates the presence of residue, recurrence, or metastasis [4] .
The aim of the present study was to establish the rate of malignancy in residual thyroid tissue in patients with DTC as well as to investigate whether or not some factors such as serum Tg level before completion thyroidectomy and histopathologic characteristics of the tumor could anticipate the presence of malignancy in residual tissue.
Material and Methods
The present retrospective study was approved by the Ethics Committee of Ankara Numune bilateralism, extrathyroidal invasion, thyroid capsular invasion, and vascular invasion), serum TSH, Tg, and anti-Tg levels before completion thyroidectomy were recorded.
Patients were divided into 2 groups according to the pathological findings of residual tissue following completion thyroidectomy; the first group consisted of the patients with malignant residual tissue, and the second group consisted of the patients with benign residual tissue. The study groups were compared with respect to demographic characteristics of patients, serum
Tg levels before completion thyroidectomy, and histopathological characteristics of the primary tumor. There were no thyroid nodules in residual thyroid tissue in any of the patients.
Being under the age of 18, receiving RAI therapy before completion thyroidectomy, having distant metastases, high anti-Tg levels, and presence of Hashimoto's thyroiditis were the exclusion criteria.
Laboratory Assays: Serum free triiodothyronine (fT3), free thyroxine (fT4), TSH, Tg, and anti-Tg concentrations were measured using paramagnetic particle, chemiluminescence immunoassays (Unicel DxI 800, Beckman Coulter, Brea, CA, USA). The normal reference range was 0.34-4.25 μIU/mL for TSH level, 2.5-3.9 pg/mL for fT3 level, 0.61-1.2 pg/mL for fT4 level, <2 ng/mL for Tg level, and 0-115 IU/mL for anti-Tg level.
In patients receiving levothyroxine, the treatment was stopped 4 weeks before the measurements of Tg and TSH. Before the completion thyroidectomy, ultrasonographic examination of the neck was performed using a high-resolution ultrasound device (Loqic 3, General Electric, USA). Residual thyroid volume of the patients was calculated using the following formula: width (cm) x depth (cm) x height (cm) x π/6 [5] .
Statistical Analysis: Data analysis was performed using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA) version 13.0. Kolmogrov-Smirnov test was used to test the normality of distribution of the measurable parameters. Data were expressed as mean ± standard deviation for normally distributed continuous variables, whereas continuous variables which did not distribute normally were shown as median (minimum-maximum).
Percentages were used for categorical variables. When comparing the groups Student t Test was used for the normally distributed subset, and Mann-Whitney U test was used for the abnormally distributing subset. Logistic regression analysis was used to determine the Multifocality was detected in 27.6% of the patients, thyroid capsular invasion in 27.6%, vascular invasion in 12.1%, and perithyroidal invasion in 6.9%. Residual thyroid volume and laboratory results before completion surgery: The median residual thyroid volume was 2.6 mL (range, 0.3-20 mL), the median TSH level was 24 μIU/mL (range, 0.4-100 μIU/mL), and the median Tg level was 10 ng/mL (range, 0.2-421 ng/mL). Tg level was <2 ng/mL in 17.2%, between 2-10 ng/mL in 31%, and >10 ng/mL in 51.7% of the patients. There were no significant differences between the two groups with respect to age, primary tumor type, tumor size, presence of bilateralism, multifocality, thyroid capsular invasion, vascular invasion, and perithyroidal invasion (p>0.05 for all). Female/male ratio was significantly lower in malignant residual tissue group (Table 2 ). There were no significant differences between the study groups in terms of the time interval for completion thyroidectomy, as well as TSH, Tg, and Tg subgroups (Table 3) . Residual thyroid volume was higher in malignant residual tissue group than in benign residual tissue group (5.4.±2.8 vs.
2.8±2.8, respectively; p=0.014) ( Table 3 ). In multivariate binary logistic regression analysis, only residual thyroid volume could independently predict the existence of residual malignancy (Table 4) . The extend of thyroid surgery in patients with DTC is a controversial issue. Total thyroidectomy is associated with a higher operative risk whereas partial thyroidectomy has the risk of leaving residual malignancy. Additionally, complete surgery improves the patient outcome and makes follow-up with serum Tg and RAI scanning more reliable [6, 7] . In previous studies, the rate of tumor detection in residual tissue after completion thyroidectomy has been reported between 20-77% [8] [9] [10] [11] [12] . In the present study, 22.4% of the patients had tumor in the residual tissue.
Completion thyroidectomy is recommended within 5 days after the first operation or after waiting for 3-4 months to diminish scar, inflammation, and edema [13] [14] [15] . In the present study, the median time to completion thyroidectomy was 5 months. The variability of time for completion thyroidectomy in our study was due to the fact that the initial operation of the patients was performed in different centers and patients were admitted to our clinic in variant periods after initial thyroidectomy.
Kim et al. [16] assessed a number of clinical and pathological variables for their ability to predict the presence of malignancy in the opposite residual lobe after hemithyroidectomy.
Among all factors studied, only presence of multifocal disease at initial surgery was found to be a significant predictor for the presence of malignancy in opposite lobe. Similarly, in another study [17] , multifocality was a significant predictor of tumor presence in the residual tissue with a rate of 57.7%. Age, gender, tumor histology, tumor size, thyroid capsular invasion, vascular invasion, and categorized serum Tg levels (Tg <2ng/mL, 2-10 ng/mL, and >10 ng/mL) were not significant predictive factors in that study. In the study by Alzahrani et al. [11] conducted in 101 patients with DTC undergoing completion thyroidectomy, predicting factors for malignancy were evaluated. They found that multifocality and serum Tg level >20 ng/mL were significant predictors for malignancy in residual thyroid tissue. In the present study, age, sex, primary tumor type, tumor size, bilateralism, multifocality, thyroid capsular invasion, vascular invasion, perithyroidal invasion, serum TSH and Tg levels before completion thyroidectomy could not predict the tumor presence in residual thyroid tissue.
When we categorized the Tg levels (<2 ng/mL, 2-10 ng/mL, and >10 ng/mL), no significant differences were detected between benign and malign residue groups with respect to Tg subgroups. Our study, for the first time, showed that residue volume was a predictor factor for malignancy in residual thyroid tissue. In conclusion, residue volume seems to a predicting factor for malignancy in residual thyroid tissue. However, further large scale studies are needed for clinical application of our results.
